Skip to main content

NeuroMusculoskeletal Institute

Research at NMI

An Osteopathic Approach to Clinical Trials

Clinicians and researchers at the NMI are deeply involved in investigations and clinical trials that target advancements in pain management. Most of our patient population has a long-standing relationship with our practice, offering us the abililty to easily connect a large, diverse population to clinical trials.

We work closely with RowanSOM's Clinical Trials Department, which is conveniently located in the same building. The Clinical Trials Department acts as an in-house contract research organization, providing 24-hour support from a nursing staff and departmental coordinator. 

Recent clinical trials at the NMI include:
  • Extension study to evaluate the long-term safety and ef cacy of Elagolix in subjects with moderate to severe endometriosis associated pain. (Abbvie, 2/15)
  • An open-label extension study of DS-5565 for 52 weeks in pain associated with bromyalgia. (Daiichi Sankyo, 1/15)
  • A randomized, double-blind, double-dummy, placebo-controlled, active-controlled, parallel-group, multi-center trial of oxycodone/naloxone controlled-release tablets (OXN) to assess the analgesic efficacy and the management of opioid- induced constipation in opioid-experienced subjects with uncontrolled moderate to severe chronic low back pain and a history of opioid-induced constipation who require around-the-clock therapy. (Purdue Pharma, 1/15)
  • Prospective, double-blind, placebo-controlled, randomized multi-center study with an open-label extension period to investigate the efficacy and safety on NT201 in the treatment of post-stroke spasticity of the upper limb. (Merz Pharmaceuticals, 7/13-3/14)
  • Dysport 2 ml for treatment of cervical dystonia. (Ipsen, 8/13)